Allogene Therapeutics (ALLO) Assets Average (2018 - 2026)

Allogene Therapeutics has reported Assets Average for 9 years, with the latest figure at $405.9 million in Q1 2026.

• Quarterly Assets Average fell 23.17% year-over-year to $405.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $405.9 million (down 23.17% YoY) and the FY2025 annual result came in at $482.3 million, down 19.05% from the prior year.
• Assets Average eased to $405.9 million in Q1 2026 per ALLO's latest filing, from $427.8 million in the prior quarter.
• Over five years, Assets Average peaked at $1.0 billion in Q1 2022 and troughed at $405.9 million in Q1 2026.
• A 5-year average of $674.0 million and a median of $618.0 million in 2024 frame the typical range for Assets Average.
• The widest YoY moves for Assets Average: up 14.03% in 2025, down 26.35% in 2025.
• Over 5 years, Assets Average stood at $858.0 million in 2022, then slipped by 20.97% to $678.1 million in 2023, then fell by 16.1% to $568.9 million in 2024, then fell by 24.8% to $427.8 million in 2025, then fell by 5.12% to $405.9 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $405.9 million, $427.8 million, and $455.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.